Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score

Supportive Care in Cancer

Volumn 4, Issue 6, 1996, Pages 435-439

  Grunberg, Steven M ^a,d   Boutin, Nancy ^a   Ireland, Anne ^b   Miner, Stella ^a   Silveira, Joyce ^a   Ashikaga, Takamaru ^c  

^a UNIVERSITY OF VERMONT   (United States)

^b Oncology Associates   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Nausea vomiting; Quality of life; Rating scale; Utility score

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; NAUSEA; NEOPLASM; PAIN ASSESSMENT; PILOT STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PAIN MEASUREMENT; PILOT PROJECTS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; VOMITING;

EID: 0030278776     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01880641     Document Type: Article

References (16)

1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208
2. Hornberger JC, Redelmeier DA, Petersen J (1992) Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 45:505-512
3. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CB, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340
4. Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, Ciampi A, Till JE, Boyd NF (1984) Describing health states - methodologic issues in obtaining values for health states. Med Care 22:543-552
5. Loomes G, McKenzie L (1989) The use of QALYs in health care decision making. Soc Sci Med 28:299-308
6. Nord E (1992) Methods for quality adjustment of life years. Soc Sci Med 34:559-569
7. O'Leary JF, Fairclough DL, Jankowski MK, Weeks JC (1995) Comparison of time-tradeoff utilities and rating scale values in cancer patients and their relatives: evidence for a possible plateau relationship. Med Decis Making 15:132-137
8. Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC (1984) Preferences for health outcomes - comparison of assessment methods. Med Decis Making 4:315-329
9. Richardson J (1994) Cost utility analysis: what should be measured? Soc Sci Med 39:7-21
10. Robinson R (1993) Cost-utility analysis. BMJ 307:859-862
11. Sutherland HJ, Dunn V, Boyd NF (1983) Measurement of values for states of health with linear analog scales. Med Decis Making 3:477-487
12. Torrance GW (1986) Measurement of health state utilities for economic appraisal - a review. J Health Econ 5:1-30
13. Van der Donk J, Levendag PC, Kuijpers AJ, Roest FHJ, Habbema JDF, Meeuwis CA, Schmitz PIM (1995) Patient participation in clinical decision-making for treatment of T3 laryngeal cancer: a comparison of state and process utilities. J Clin Oncol 13:2369-2378
14. Weeks J (1995) Measurement of utilities and quality-adjusted survival. Oncology 9 [Suppl 11]:67-70
15. Weeks JC (1995) Special issues that arise in applying techniques of economic analysis to evaluation of cancer therapies. Monogr Natl Cancer Inst 19:11-12
16. Zbrozek AS, Cantor SB, Cardenas MP, Hill DP Jr (1994) Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 51:1555-1563